PMID- 32064642
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1398-9995 (Electronic)
IS  - 0105-4538 (Linking)
VI  - 75
IP  - 5
DP  - 2020 May
TI  - Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and 
      omalizumab) for severe allergic asthma: A systematic review for the EAACI 
      Guidelines - recommendations on the use of biologicals in severe asthma.
PG  - 1043-1057
LID - 10.1111/all.14235 [doi]
AB  - Allergic asthma is a frequent asthma phenotype. Both IgE and type 2 cytokines are 
      increased, with some degree of overlap with other phenotypes. Systematic reviews 
      assessed the efficacy and safety of benralizumab, dupilumab and omalizumab 
      (alphabetical order) vs standard of care for patients with uncontrolled severe 
      allergic asthma. PubMed, Embase and Cochrane Library were searched to identify 
      RCTs and health economic evaluations, published in English. Critical and 
      important asthma-related outcomes were evaluated. The risk of bias and the 
      certainty of the evidence were assessed using GRADE. All three biologicals 
      reduced with high certainty the annualized asthma exacerbation rate: benralizumab 
      incidence rate ratios (IRR) 0.63 (95% CI 0.50 - 0.81); dupilumab IRR 0.58 (95%CI 
      0.47 - 0.73); and omalizumab IRR 0.56 (95%CI 0.42 - 0.73). Benralizumab and 
      dupilumab improved asthma control with high certainty and omalizumab with 
      moderate certainty; however, none reached the minimal important difference (MID). 
      Both benralizumab and omalizumab improved QoL with high certainty, but only 
      omalizumab reached the MID. Omalizumab enabled ICS dose reduction with high 
      certainty. Benralizumab and omalizumab showed an increase in drug-related adverse 
      events (AEs) with low to moderate certainty. All three biologicals had moderate 
      certainty for an ICER/QALY value above the willingness to pay threshold. There 
      was high certainty that in children 6-12 years old omalizumab decreased the 
      annualized exacerbation rate [IRR 0.57 (95%CI 0.45-0.72)], improved QoL [relative 
      risk 1.43 (95%CI 1.12 -1.83)], reduced ICS [mean difference (MD) -0.45 (95% CI 
      -0.58 to -0.32)] and rescue medication use [ MD -0.41 (95%CI -0.66 to -0.15)].
CI  - (c) 2020 John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
FAU - Agache, Ioana
AU  - Agache I
AUID- ORCID: 0000-0001-7994-364X
AD  - Faculty of Medicine, Transylvania University, Brasov, Romania.
FAU - Rocha, Claudio
AU  - Rocha C
AD  - Iberoamerican Cochrane Centre , Department of Clinical Epidemiology and Public 
      Health, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
FAU - Beltran, Jessica
AU  - Beltran J
AD  - Iberoamerican Cochrane Centre , Department of Clinical Epidemiology and Public 
      Health, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
FAU - Song, Yang
AU  - Song Y
AD  - Iberoamerican Cochrane Centre , Department of Clinical Epidemiology and Public 
      Health, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
FAU - Posso, Margarita
AU  - Posso M
AD  - Iberoamerican Cochrane Centre , Department of Clinical Epidemiology and Public 
      Health, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
AD  - Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical 
      Research Institute), Barcelona, Spain.
FAU - Sola, Ivan
AU  - Sola I
AD  - Iberoamerican Cochrane Centre , Department of Clinical Epidemiology and Public 
      Health, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
FAU - Alonso-Coello, Pablo
AU  - Alonso-Coello P
AD  - Iberoamerican Cochrane Centre , Department of Clinical Epidemiology and Public 
      Health, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
AD  - CIBER de Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain.
FAU - Akdis, Cezmi
AU  - Akdis C
AUID- ORCID: 0000-0001-8020-019X
AD  - Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, 
      Davos, Switzerland.
FAU - Akdis, Mubeccel
AU  - Akdis M
AUID- ORCID: 0000-0003-0554-9943
AD  - Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, 
      Davos, Switzerland.
FAU - Canonica, Giorgio W
AU  - Canonica GW
AD  - Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research 
      Center, IRCCS, Rozzano, Italy.
FAU - Casale, Thomas
AU  - Casale T
AUID- ORCID: 0000-0002-3149-7377
AD  - Division of Allergy and Immunology, University of South Florida Morsani College 
      of Medicine, Tampa, FL, USA.
FAU - Chivato, Tomas
AU  - Chivato T
AD  - School of Medicine, University CEU San Pablo, Madrid, Spain.
FAU - Corren, Jonathan
AU  - Corren J
AD  - David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
FAU - Del Giacco, Stefano
AU  - Del Giacco S
AD  - Department of Medical Sciences and Public Health, University of Cagliari, Italy, 
      Monserrato.
FAU - Eiwegger, Thomas
AU  - Eiwegger T
AUID- ORCID: 0000-0002-2914-7829
AD  - Translational Medicine Program, Research Institute, Hospital for Sick Children, 
      Toronto, ON, Canada.
AD  - Department of Immunology, University of Toronto, Toronto, ON, Canada.
AD  - Division of Immunology and Allergy, Food Allergy and Anaphylaxis Program, The 
      Hospital for Sick Children, Departments of Paediatrics and Immunology, University 
      of Toronto, Toronto, ON, Canada.
FAU - Firinu, Davide
AU  - Firinu D
AUID- ORCID: 0000-0002-5768-391X
AD  - Department of Medical Sciences and Public Health, University of Cagliari, Italy, 
      Monserrato.
FAU - Gern, James E
AU  - Gern JE
AD  - Department of Pediatrics, University of Wisconsin School of Medicine and Public 
      Health, Madison, WI, USA.
FAU - Hamelmann, Eckard
AU  - Hamelmann E
AUID- ORCID: 0000-0002-2996-8248
AD  - Klinik fur Kinder- und Jugendmedizin Kinderzentrum Bethel, Bielefeld, Germany.
FAU - Hanania, Nicola
AU  - Hanania N
AD  - Section of Pulmonary, Critical Care and Sleep Medicine, Baylor College of 
      Medicine, Houston, Texas, USA.
FAU - Makela, Mika
AU  - Makela M
AD  - Skin and Allergy Hospital, Helsinki University Hospital and University of 
      Helsinki, Helsinki, Finland.
FAU - Martin, Irene Hernandez
AU  - Martin IH
AD  - Department of Allergy, Hospital Universitario La Paz, Madrid, Spain.
FAU - Nair, Parameswaran
AU  - Nair P
AUID- ORCID: 0000-0002-1041-9492
AD  - Division of Respirology, Department of Medicine, McMaster University, Hamilton, 
      ON, Canada.
AD  - Firestone Institute for Respiratory Health, St Joseph's Healthcare, Hamilton, ON, 
      Canada.
FAU - O'Mahony, Liam
AU  - O'Mahony L
AUID- ORCID: 0000-0003-4705-3583
AD  - Departments of Medicine and Microbiology, APC Microbiome Ireland, University 
      College Cork, Cork, Ireland.
FAU - Papadopoulos, Nikolaos G
AU  - Papadopoulos NG
AUID- ORCID: 0000-0002-4448-3468
AD  - Division of Infection, Immunity & Respiratory Medicine, University of Manchester, 
      Manchester, UK.
AD  - Allergy Department, 2nd Pediatric Clinic, National Kapodistrian University of 
      Athens, Athens, Greece.
FAU - Papi, Alberto
AU  - Papi A
AD  - Research Center on Asthma and COPD, Department of Medical Sciences, University of 
      Ferrara, Ferrara, Italy.
FAU - Park, Hae-Sim
AU  - Park HS
AUID- ORCID: 0000-0003-2614-0303
AD  - Department of Allergy and Clinical Immunology, Ajou University, Suwon, South 
      Korea.
FAU - Perez de Llano, Luis
AU  - Perez de Llano L
AUID- ORCID: 0000-0003-2652-6847
AD  - Department of Respiratory Medicine, Hospital Lucus Augusti, Lugo, Spain.
FAU - Quirce, Santiago
AU  - Quirce S
AD  - Department of Allergy, La Paz University Hospital, IdiPAZ, CIBER of Respiratory 
      Diseases (CIBERES), Universidad Autonoma de Madrid, Madrid, Spain.
FAU - Sastre, Joaquin
AU  - Sastre J
AUID- ORCID: 0000-0003-4689-6837
AD  - Universidad Autonoma de Madrid Facultad de Medicina, Madrid, Spain.
FAU - Shamji, Mohamed
AU  - Shamji M
AUID- ORCID: 0000-0003-3425-3463
AD  - Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, 
      Inflammation, Repair, Development, National Heart and Lung Institute, London, UK.
AD  - Imperial College NIHR Biomedical Research Centre, UK Centre in Allergic 
      Mechanisms of Asthma, London, UK.
FAU - Schwarze, Jurgen
AU  - Schwarze J
AD  - Centre for Inflammation Research, Child Life and Health, The University of 
      Edinburgh, Edinburgh, UK.
FAU - Canelo-Aybar, Carlos
AU  - Canelo-Aybar C
AD  - Iberoamerican Cochrane Centre , Department of Clinical Epidemiology and Public 
      Health, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
AD  - Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, 
      Davos, Switzerland.
FAU - Palomares, Oscar
AU  - Palomares O
AUID- ORCID: 0000-0003-4516-0369
AD  - Department of Biochemistry and Molecular Biology, Chemistry School, Complutense 
      University of Madrid, Madrid, Spain.
FAU - Jutel, Marek
AU  - Jutel M
AD  - University of Wroclaw, Department of Clinical Immunology, Wroclaw, Poland.
AD  - "ALL-MED" Medical Research Institute, Wroclaw, Poland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Biological Products)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 420K487FSG (dupilumab)
RN  - 71492GE1FX (benralizumab)
SB  - IM
MH  - *Anti-Asthmatic Agents/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - *Asthma/drug therapy
MH  - *Biological Products/adverse effects
MH  - Child
MH  - Humans
MH  - Omalizumab/adverse effects
MH  - Quality of Life
OTO - NOTNLM
OT  - benralizumab
OT  - dupilumab
OT  - exacerbations
OT  - omalizumab
OT  - severe allergic asthma
EDAT- 2020/02/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/02/18 06:00
PHST- 2020/02/04 00:00 [received]
PHST- 2020/02/11 00:00 [accepted]
PHST- 2020/02/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/02/18 06:00 [entrez]
AID - 10.1111/all.14235 [doi]
PST - ppublish
SO  - Allergy. 2020 May;75(5):1043-1057. doi: 10.1111/all.14235.